15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Gaurav ChatterjeePriyanka DhendeSimpy RajVruksha ShettySitaram GhogaleNilesh DeshpandeKarishma GiraseJagruti PatilAastha KalraGaurav NarulaKajal DalviChetan DhamneNirmalya Roy MoulikSweta RajpalNikhil V PatkarShripad BanavaliSumeet GujralPapagudi G SubramanianPrashant Ramesh TembharePublished in: European journal of haematology (2023)
We standardized a highly sensitive 15-color BMRD assay with a non-CD19-based gating strategy for patients receiving anti-CD19 immunotherapy. We also described the immunophenotypes of recurrently occurring low-level populations that can be misinterpreted as MRD in real-world practice.